Medicenna Therapeutics (MDNA) AGM 2024 summary

Opening remarks and agenda

• Meeting opened with introductions of board members and management, including a new board member and key executives.

• The meeting was held virtually for efficiency and to ensure broad shareholder participation.

• Rules for conduct, voting, and Q&A were outlined, with voting and questions restricted to registered shareholders and proxyholders.

• Quorum was confirmed, and the agenda followed the management information circular dated August 14, 2024.

Board and executive committee updates

• Board nominees for the coming year were presented: Albert Beraldo, Karen Dawes, Jack Geltosky, John Buchan, Karim Lalji, and Fahar Merchant.

• All nominees had consented to act as directors if elected.

Overview of voting outcomes

• Voting was conducted by ballot, with all registered shareholders and proxyholders able to participate virtually.

• All director nominees were elected, and MNP LLP was appointed as auditor for the next fiscal year.

• Resolutions were declared carried, with final voting results to be disclosed in a press release and SEDAR+ filing.